Navigation Links
New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
Date:5/16/2008

LCADE is approved in 85 countries worldwide. More than 85,000 patients have been treated with VELCADE globally.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving VELCADE. RPLS is a rare, reversible, neurological di
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
2. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
3. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
4. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
5. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
6. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
7. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
8. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
9. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
10. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
11. Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" or the ... announced today that Dr. Robert Grieve , ... Jason Napolitano , executive vice president and chief financial ... which is being held May 30, 2013 in ... The Company,s presentation is scheduled to begin ...
(Date:5/24/2013)... May 24, 2013 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China ... learned from a public announcement issued by Shanghai RAAS ... listed on Shenzhen Stock Exchange, that on May 21, ... ("Ms. Chan"), one of the shareholders of the Company, ...
(Date:5/24/2013)... CHESTERBROOK, Pa. , May 24, 2013  Auxilium ... that executive management will participate in the Deutsche Bank ... the Westin Boston Waterfront Hotel.  Mr. Adrian ... scheduled to present an overview of the Company and ... May 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4
... Campath May Lead to Overall Survival in Patients with Poor ... FRANCISCO, Dec. 9 Bayer HealthCare Pharmaceuticals Inc. today announced ... showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who ... 50th Annual Meeting of the American Society of Hematology in ...
... 8 Millennium: The Takeda Oncology Company today ... of patients from the large, international Phase III ... with previously untreated multiple myeloma given VELCADE, melphalan ... efficacy in all patient sub-groups, including those with ...
Cached Medicine Technology:Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
(Date:5/24/2013)... Just about any bodyweight training program includes a variety of ... Dallas, GA that uses a variety of bodyweight conditioning circuits ... used enough. , “The medicine ball pushup is ... By keeping your hands on a medicine ball, the core ... much harder than a standard pushup. This unique bodyweight chest ...
(Date:5/24/2013)... 24, 2013 For the second consecutive ... Fresh Express Café to treat Tabitha Meals on Wheels ... their door. More than 400 meal recipients recently enjoyed ... restaurants, along with the rest of a well-balanced, nutritious ... to partner with the Tabitha Meals on Wheels team,” ...
(Date:5/24/2013)... have today released updated guidelines on Hormone Replacement Therapy ... the benefits and the risks. The new guidelines appear ... published by SAGE. , Over the last 11 ... of youth" to being considered extremely risky and only ... of the Women,s Health Initiative (WHI) trial in 2002, ...
(Date:5/24/2013)... Bridal Buy , a leading wedding ... 2013 bridesmaid dresses are available in its wedding ... featured as fine fabrics, elegant beading, and exquisite embroidery. ... and an eye for detailed designs. However, our lace ... life from patterns and the hands of dressmakers,” said, ...
(Date:5/24/2013)... Psoriasis treatment cream has been released online for ... registered company is now offering its natural solution to ... infected skin. , Dermasis has launched its new psoriasis ... cream is designed to offer immediate relief to those ... red skin often caused by psoriasis outbreaks. This new ...
Breaking Medicine News(10 mins):Health News:Medicine Ball Pushups, a Unique Bodyweight Chest Exercise, Released in Video from BodyweightTorch.com 2Health News:Runza® Delivers Sandwiches, Draws Smiles from Tabitha Meals on Wheels Clients 2Health News:Dermasis Psoriasis Treatment Cream for Men and Women Released Online at HealthCareSupplementz.com 2
... , SAN DIEGO, July 21 ... Anakam.TFA(R) Two-Factor Authentication as the enterprise authentication tool for ... to help the VA provide more veteran-centric benefit and ... cost-effective citizen-facing two-factor authentication solution delivered through multiple channels ...
... , , , ... historic show of unity, advocates for all the health Millennium Development Goals ... commitments to health by chronically underfunding programs for AIDS, TB, maternal and ... globe. , , The coalition of ...
... , BALTIMORE, July 21 Stayhealthy, Inc., a leader ... take control of their health, and Innovative Wellness Solutions a leader ... have reached an agreement to bring a powerful new solution to ... , , Wellness in the workplace ...
... SHENZHEN, China, July 21 /PRNewswire-Asia-FirstCall/ -- ... the,Company has changed its name to "BioPharm Asia, Inc." ... place in the next three to four weeks,in accordance ... name change to BioPharm Asia, Inc. will be reflected ...
... , , MONROVIA, Calif., July ... developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that ... Division of Bioresearch Monitoring that the restrictions of the "integrity hold" put ... The removal of the integrity hold enables the FDA to resume ...
... , , NEW YORK, July 21 ... cleanse Food & Wine Magazine recently dubbed ... State by announcing today that it will offer free delivery to anywhere in ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090721/LA49137 ) , , ...
Cached Medicine News:Health News:Department of Veterans Affairs Selects Anakam to Provide Trusted Authentication as Part of Its Overall Identity Management Strategy 2Health News:Department of Veterans Affairs Selects Anakam to Provide Trusted Authentication as Part of Its Overall Identity Management Strategy 3Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 2Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 3Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 4Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 5Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 6Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 7Health News:Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments 8Health News:Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 2Health News:Stayhealthy and Innovative Wellness Solutions Announce Partnership to Bring Innovation to the Workplace Wellness Market 3Health News:Domain Registration Corp. Announces Name Change to 'BioPharm Asia, Inc.' 2Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 2Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 3Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 4Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 5Health News:BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 2Health News:BluePrintCleanse to Create a Juice Rush With Free Shipping to State of California 3
5mSports™ is the handheld version of 5 Minute Sports Medicine Consult, your favorite reference for on-field and off-field treatment of sports related problems....
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
... the essential information that every intern ... wards, including the neurologic history and ... neuroimaging techniques and diagnostic tools, and ... dizziness, and ataxia, acute vision loss, ...
... all-original guide prepared specifically for ... from "PocketMedicine/Internal Medicine", it will ... those training in the field, ... are frequently the first to ...
Medicine Products: